

AF1653

**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of

Docket No: Q62621

Satoshi SASAKI, et al.

Appln. No.: 09/744,328

Group Art Unit: 1653

Confirmation No.: 4446

Examiner: Chih Min Kam

Filed: January 23, 2001

For: PHARMACEUTICAL COMPOSITION HAVING INHIBITORY EFFECT ON  
OVERPRODUCTION AND ACCUMULATION OF EXTRACELLULAR MATRIX

**STATEMENT OF SUBSTANCE OF INTERVIEW**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Please review and enter the following remarks summarizing the interview conducted on  
March 30, 2004:

**REMARKS**

An Examiner's Interview Summary Record (PTO-413) given personally to the  
undersigned at the conclusion of the interview on March 30, 2004.

During the interview, the following was discussed:

1. Brief description of exhibits or demonstration: None.
2. Identification of claims discussed: Claims 1 and 25.

Statement of Substance of Interview  
U.S. Serial No.: 09/744,328

3. Identification of art discussed: None.

4. Identification of principal proposed amendments: The examiners proposed amending claims 1 and 25 to identify the compound that inhibits the biological activity of galectin-3 as a compound that inhibits the binding of galectin-3 to sugars.

5. Brief Identification of principal arguments: The undersigned argued that the amendment filed by January 30, 2004, should have been entered because, contrary to the examiners' position, amending claim 25 to recite a method of therapeutic or preventive treatment in place of a method for inhibition of various diseases, does not raise a new issue of patentability. The undersigned asserted that a method for inhibition of a disease would include preventative treatment.

6. Indication of other pertinent matters discussed: The examiners and the undersigned discussed the types of compounds that inhibit the biological activity of galectin-3 in the pharmaceutical composition and in the method of treatment. The examiners and the undersigned also discussed extrapolating *in vitro* data to *in vivo* effect.


7. Results of Interview: No agreement was reached.

**It is believed that no petition or fee is required.** However, if the USPTO deems otherwise, Applicant hereby petitions for any extension of time which may be required to

Statement of Substance of Interview  
U.S. Serial No.: 09/744,328

maintain the pendency of this case, and any required fee, except for the Issue Fee, for such extension is to be charged to Deposit Account No. 19-4880.

Respectfully submitted,



Susan J. Mack  
Registration No. 30,951

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE

**23373**

CUSTOMER NUMBER

Date: April 30, 2004